Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].

Abstract: A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2 in high concentrations is provided. This composition comprises WAP-8294A2 of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-?-cyclodextrin or ?-cyclodextrin is contained as a stabilizer or solubilizer and the pH of the composition is not adjusted. This composition is mixed with a pH-adjusting agent such as dextrose and with an infusion or diluent comprising a solution of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium hydroxide at the time of use to prepare a solution for intravenous administration of WAP-8294A2.

Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].

Abstract: A method for the treatment and prevention of herpes zoster using 5-[(E)-2-halogenovinyl] arabinofuranosyl uracil of the following general formula (1): wherein X represents a halogen atom.

Abstract: A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2 in high concentrations is provided. This composition comprises WAP-8294A2 of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-?-cyclodextrin or ?-cyclodextrin is contained as a stabilizer or solubilizer and the pH of the composition is not adjusted. This composition is mixed with a pH-adjusting agent such as dextrose and with an infusion or diluent comprising a solution of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium hydroxide at the time of use to prepare a solution for intravenous administration of WAP-8294A2.

Abstract: A method for the treatment and prevention of herpes zoster using 5-[(E)-2-halogenovinyl]arabinofuranosyl uracil of the following general formula (1): wherein X represents a halogen atom.

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: 1

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

Abstract: The present invention relates to 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosines having excellent antitumor activity, represented by formula [I]: ##STR1## wherein R represents a hydrogen atom or a phosphoric acid residue, and to a process for the production and use thereof.

Abstract: The present invention relates to 9-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)purine derivatives having antiviral activity, represented by formula [I]: ##STR1## wherein B represents a base selected from the group consisting of purine, azapurine and deazapurine, which may be substituted with halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, alkylamino, hydroxyl, hydroxyamino, aminoxy, alkoxy, mercapto, alkylmercapto, aryl, aryloxy or cyano; and R represents a hydrogen atom or a phosphoric acid residue, and to a process for the production and use thereof.

Abstract: The present invention provides a novel purine 4'-thioarabinonucleoside represented by the following formula ?1!: ##STR1## wherein B represents a purine base other than adenine. Also disclosed are a method for preparing the purine 4'-thioarabinonucleoside and pharmaceutical compositions containing the purine 4'-thioarabinonucleoside.

Abstract: A converter for raising a weak input DC voltage of 0.3 volts or less to an output voltage has a blocking oscillator and a field-effect transistor included in the oscillator. The transistor having a base earthed is of the enhancement type activated by a gate-source voltage equal to or lower than the input, and the oscillator is activated responding to the gate-source voltage, so that pulses are generated as the output. Typically, the oscillator is composed of a resistor and a condenser connected in series through a lead and between an earth and an input line, a transformer whose secondary winding is connected to transistor's gate and the lead, with a primary winding being connected to the input line and the transistor's drain, and a diode earthed and having a cathode connected to the gate. An electromotive force induced through the secondary winding when the transistor is inactivated has positive and negative poles directed to the condenser and the gate, respectively.

Abstract: The image sensor according to the present invention comprises a light emitting diode which irradiates light onto a document image, a phototransistor which receives the reflected light and executes photoelectric conversion, an amplifier which amplifies an analog signal from the phototransistor, a time constant circuit into which an analog signal from the amplifier is inputted and which delays the analog signal by a specified period of time, an amplifier into which the analog signal outputted from the amplifier and the analog signal delayed in the time constant circuit are inputted and which differentially amplifies the analog signals, and a knot gate into which the analog signals outputted from the amplifier are inputted and which outputs a digital signal of "0" or "1" according to whether a value for the analog signal is positive or negative.

Abstract: A laser bar code system is described which includes a first scan module releasably affixed to a housing, which scan module is readily interchangeable with and plug compatible with a second scan module which is configured at least partly differently from the first scan module. In addition, a partitioned scan module is described which comprises a first laser diode subsystem, a first scanning subsystem, a first collection subsystem, and a first signal processing subsystem, a selected one of which is releasably affixed to a chassis, and readily interchangeable and plug compatible with a second laser diode subsystem, a second scanning subsystem, a first collection subsystem, and a second signal processing subsystem, respectively, which is configured at least partly differently from the first.

Abstract: The present invention relates to a novel 1-.beta.-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivative represented by the following formula (I), whose concentration in blood as XVAU can be kept high for many hours when it is administered orally.The present invention also relates to an antiviral agent comprising as an active ingredient the compound of the present invention.Further, the present invention relates to a method for treating viral diseases which comprises administering to a patient with a viral disease a safe and effective amount of the compound of the present invention. ##STR1## wherein X represents a halogen; and R.sup.1, R.sup.2, and R.sup.3, which may be the same or different, each represent a hydrogen atom, a lower alkyl group or an aralkyl group, provided that R.sup.1, R.sup.2 and R.sup.3 are not hydrogen at the same time.

Abstract: Disclosed are novel 2'-alkylidenepyrimidine nucleoside derivatives represented by formula [I]: ##STR1## R.sup.1 is an amino group or a hydroxy group, R.sup.2 is a hydrogen atom, a halogen atom or a lower alkyl group, R.sup.3 is a hydrogen atom or a lower alkyl group, and R.sup.4 is a hydrogen atom or a phosphate residue, or salts thereof. These novel compounds can be produced from uridine or cytidine derivatives by alkylidenating the 2'-position in the sugar moiety thereof with Wittig's reagent. Furthermore, the compounds have remarkable antiviral activities and therefore can provide novel antiviral agents.

Abstract: An optical movement measuring method and apparatus measures a movement of an object. A light from a light source is irradiated on a diffraction grating which is provided on the object so as to generate diffracted lights of different order of diffraction. The diffraction grating has light transmitting portions and light blocking portions which are alternately and periodically arranged. Interference fringes which comprises bright and dark stripes which occur alternately and are generated by overlapping spots of diffracted lights of different order of diffraction are detected, and a movement of the object is measured based on a counted number of stripes of the detected interference fringes.

Abstract: Disclosed are novel 2'-alkylidenepyrimidine nucleoside derivatives represented by formula [I]: ##STR1## wherein R.sup.1 is an amino group or a hydroxy group, R.sup.2 is a hydrogen atom, a halogen atom or a lower alkyl group, R.sup.3 is a hydrogen atom or a lower alkyl group, and R.sup.4 is a hydrogen atom or a phosphate residue, or salts thereof.These novel compounds can be produced from uridine or cytidine derivatives by alkylidenating the 2'-position in the sugar moiety thereof with Wittig's reagent.Furthermore, the compounds have remarkable antiviral activities and therefore can provide novel antiviral agents.

Abstract: In a method for detecting a moving amount of a detected body, light emitted from a light source is irradiated onto the detected body and light reflected from the detected body or light transmitted therethrough is detected by a photodetector. This method has the steps of emitting incoherent light from the light source through a small opening of a light-interrupting plate; irradiating the incoherent light onto the detected body having a monoperiodic structure to obtain a divergent transmitting or reflecting light beam; forming a shadow picture diffraction-interference pattern by the divergent transmitting or reflecting light beam; and detecting a moving amount of the shadow picure diffraction-interference pattern caused by a movement of the detected body in a direction crossing the irradiated light beam by the photodetector to detect the moving amount of the detected body.